Broth microdilution MIC testing for Candida & Aspergillus isolates — from raw wells to a clinical treatment decision
Unlike the relatively predictable susceptibility patterns of many bacteria to first-line antibiotics, fungal pathogens display substantial and sometimes unpredictable variation in susceptibility to antifungal drug classes. Candida albicans, Candida glabrata, and Aspergillus fumigatus can each respond very differently to the same azole, echinocandin, or polyene — even among isolates from the same species. Empiric therapy based on "typical" patterns risks treatment failure in an individual patient, which is why isolate-specific testing is central to modern antifungal stewardship.
Fungi are eukaryotes, sharing far more cellular machinery with human host cells than bacteria do. This dramatically narrows the number of unique, safely druggable targets:
• Azoles (fluconazole, voriconazole, itraconazole, posaconazole, isavuconazole): inhibit lanosterol 14-α-demethylase (Erg11/Cyp51), blocking ergosterol synthesis in the fungal membrane • Echinocandins (caspofungin, micafungin, anidulafungin): inhibit (1,3)-β-D-glucan synthase, disrupting fungal cell wall synthesis • Polyenes (amphotericin B): bind ergosterol directly, forming membrane pores • Pyrimidine analogs (flucytosine): disrupt fungal DNA/RNA synthesis after conversion to 5-fluorouracil
Compared to the dozens of distinct antibacterial mechanisms available, this narrow toolkit means that losing effectiveness of even one class through resistance has an outsized clinical impact.
Clinicians once relied heavily on species identification alone to guide empiric antifungal choice — for example, assuming all Candida albicans are fluconazole-susceptible. Surveillance data have repeatedly shown this assumption is unsafe:
• Azole-resistant C. albicans isolates are increasingly reported, especially after prior azole exposure • C. glabrata, second only to C. albicans in frequency among candidemia isolates, has intrinsically elevated fluconazole MICs and a track record of acquiring echinocandin resistance during therapy • Aspergillus fumigatus triazole resistance, once rare, has emerged in multiple regions, linked in part to agricultural azole fungicide use that pre-selects resistant environmental isolates
Because susceptibility can no longer be assumed from species identity alone, phenotypic testing of the actual clinical isolate has become a standard-of-care step for serious or refractory fungal infections.
The core clinical insight of this stage: species identification tells you what organism you are treating; susceptibility testing tells you which drug will actually work against this particular isolate in this particular patient.
Broth microdilution, standardized by CLSI documents M27 (yeasts) and M38 (filamentous molds), is the reference method for antifungal susceptibility testing. A standardized inoculum of the fungal isolate is distributed into a row of wells, each containing a two-fold serial dilution of the antifungal agent. After a defined incubation period, each well is read for visible growth (turbidity) or inhibition (clearing), building a concentration-response profile unique to that isolate.
The test is prepared as a careful, reproducible dilution series:
1. A stock solution of the antifungal drug is serially diluted two-fold across a row of wells (e.g. 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.06, 0.03 μg/mL) 2. A standardized fungal suspension, adjusted by turbidity (e.g. 0.5 McFarland equivalent) to a defined inoculum density, is added to every well including a drug-free growth control 3. A sterility control well (medium only, no organism) confirms the test medium and reagents are not contaminated 4. Plates are incubated at a controlled temperature and time appropriate to the organism — shorter for fast-growing yeasts, longer for filamentous molds that need time to visibly sporulate/branch
Because the dilution steps are exactly two-fold, each well represents a precise doubling or halving of drug concentration relative to its neighbors — this is what allows the MIC to be read as a specific, reproducible number rather than a vague range.
After incubation, each well is inspected, typically against a light box or reading mirror:
• Turbid wells: visible fungal growth — the drug concentration in that well was insufficient to inhibit the isolate • Clear wells: no visible growth — the drug concentration was sufficient to inhibit growth • For azoles against Candida, a trailing growth phenomenon can occur where faint growth persists across many wells; CLSI guidance uses a partial-inhibition endpoint (~50% reduction in turbidity relative to the growth control) rather than requiring complete clearing • For echinocandins, a similar "minimum effective concentration" reading based on abnormal, stunted hyphal/cell morphology is sometimes used instead of complete growth inhibition
The growth control well (no drug) must show robust growth, and the sterility control must remain clear, or the entire test is invalid and must be repeated.
The Minimum Inhibitory Concentration (MIC) is defined as the lowest antifungal concentration in the dilution series that prevents visible growth of the isolate under standardized test conditions. It is not a fixed property of the drug alone, nor of the species alone — it is a quantitative, isolate-specific measurement that emerges directly from the microdilution plate reading.
Reading the MIC is a systematic scan across the dilution row:
1. Confirm the growth control well shows full turbidity and the sterility control is clear (test validity check) 2. Starting from the highest drug concentration and moving toward the lowest, identify each well as inhibited (clear) or grown (turbid) 3. Because the isolate becomes progressively less inhibited as concentration falls, wells typically transition from clear → turbid moving down the series 4. The MIC is recorded as the concentration in the first well (lowest concentration) that still shows the defined inhibition endpoint — the well just below it will show growth
In practice this transition is not always perfectly sharp — occasional "skip wells" (an isolated turbid well surrounded by clear ones) can occur and are handled per CLSI interpretive rules, usually by reading the highest well showing the sustained inhibition pattern.
A key conceptual point: the MIC is not a categorical label by itself — it is a number, expressed in μg/mL, unique to the combination of this fungal isolate and this antifungal drug under these test conditions.
Two isolates of the same species, even from the same patient at different points in therapy, can have very different MIC values against the same drug — for example, if resistance emerges during prolonged antifungal exposure. This is why susceptibility testing is repeated on new isolates recovered during treatment failure, rather than assuming the original test result still applies.
The MIC value only becomes clinically actionable in the next step, when it is compared against interpretive breakpoints specific to the species and drug being tested.
A lower MIC means less drug was needed to stop visible growth — generally indicating greater susceptibility. But "low" and "high" are only meaningful relative to the breakpoints for that species/drug pair, not as an absolute number in isolation.
A raw MIC value only becomes clinically meaningful once it is compared against interpretive breakpoints — concentration thresholds established for a specific fungal species and a specific antifungal drug, derived from a combination of MIC distribution data, pharmacokinetic/pharmacodynamic modeling, and clinical outcome correlation. The same numeric MIC can be classified differently depending on which species and which drug are being tested.
Interpretive breakpoints are not arbitrary — they are derived from multiple converging lines of evidence:
• Wild-type MIC distributions: large surveillance datasets establish the normal MIC range for isolates without acquired resistance mechanisms • Pharmacokinetic/pharmacodynamic (PK/PD) modeling: predicts what drug exposure is achievable at standard doses and what MIC that exposure can realistically overcome • Clinical outcome correlation: retrospective and prospective studies link MIC values to real treatment success or failure rates
Because intrinsic drug exposure and target enzyme sensitivity differ by species, the same drug can have different breakpoints for different organisms. C. glabrata, for instance, has intrinsically higher baseline fluconazole MICs than C. albicans due to differences in efflux pump expression and drug target affinity — so CLSI does not define a true "susceptible" category for C. glabrata against fluconazole, instead using a "susceptible-dose-dependent" (SDD) category that assumes higher doses may still be effective.
Once the correct species/drug breakpoint table is selected, the isolate's MIC is classified into one of three standard categories:
• Susceptible (S): MIC at or below the susceptible breakpoint — standard dosing is expected to achieve therapeutic drug exposure exceeding the MIC • Intermediate / Susceptible-Dose-Dependent (I/SDD): MIC in an intermediate range — treatment may still succeed with a higher dose, more frequent dosing, or better drug exposure at the infection site • Resistant (R): MIC at or above the resistant breakpoint — even maximal achievable drug exposure is unlikely to exceed the MIC; a different antifungal class should be considered
For molds like Aspergillus fumigatus, formal clinical breakpoints are less established for some agents, so laboratories often use epidemiological cutoff values (ECVs) that separate wild-type (no acquired resistance mechanism) isolates from non-wild-type isolates with reduced susceptibility, which is treated as a proxy for likely reduced clinical response.
The same MIC number can be "susceptible" for one species/drug pair and "resistant" for another — the breakpoint table, not the MIC alone, determines the clinical category.
The entire testing pipeline — isolate recovery, broth microdilution, MIC determination, breakpoint interpretation — exists to answer one clinical question: which antifungal agent, at what dose, is most likely to succeed for this specific patient's infection? Susceptibility results are combined with the limited number of available antifungal drug classes, the site of infection, and the patient's clinical status to select therapy.
A susceptibility report is only useful when it changes or confirms a treatment decision:
• Susceptible result: supports continuing or starting standard-dose therapy with the tested agent, consistent with guideline-recommended first-line choices for the infection type and site • Intermediate/SDD result: prompts consideration of a higher dose, a different dosing interval, or closer monitoring for early treatment failure — particularly important when the infection site (e.g. CNS, eye) limits drug penetration • Resistant result: prompts a switch to a different antifungal class altogether, since increasing the dose of a drug the isolate is resistant to rarely overcomes the resistance mechanism
This decision is layered on top of other factors: source control (removing infected catheters, draining abscesses), the patient's renal/hepatic function (affecting drug choice and dosing), and any known drug-drug interactions.
Antifungal stewardship carries extra weight because the drug toolkit is so much narrower than for antibacterial therapy:
• Losing effectiveness of one class (e.g. widespread azole resistance in a Candida species, or emerging triazole resistance in Aspergillus fumigatus) removes a much larger fraction of total treatment options than losing one antibacterial class would • Some agents (e.g. amphotericin B) carry significant toxicity (nephrotoxicity, infusion reactions), so reserving them appropriately based on susceptibility data — rather than using them empirically for every case — matters for patient safety as well as resistance stewardship • Rising echinocandin resistance in C. glabrata is a particular concern because echinocandins are frequently used as first-line, well-tolerated therapy for invasive candidiasis — a resistant result here can meaningfully narrow options
Because of this narrow margin, susceptibility testing is not just a diagnostic afterthought — for serious or refractory fungal infections, it is often the single piece of information most likely to change what a clinician actually prescribes.
With only four major antifungal drug classes in routine clinical use, and resistance rising in some Candida species, individualized susceptibility testing plays an outsized role in preserving treatment options compared to antibacterial therapy, where many more drug classes remain available as backups.